ROYALTY PHARMA
Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma does not discover, develop, manufacture or market products. Instead, the Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with research instit... utions, inventors and biotechnology & pharmaceutical companies since 1996, and now owns royalty interests in forty four approved and marketed biopharmaceutical products and seven products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency ("EMA”).
ROYALTY PHARMA
Social Links:
Industry:
Biotechnology Manufacturing Pharmaceutical
Founded:
1996-01-01
Status:
Active
Contact:
212-883-0200
Total Funding:
0
Technology used in webpage:
SPF Google Font API Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS GoDaddy DNS Apache 2.4
Similar Organizations
Welmedix Consumer Healthcare
Welmedix Consumer Healthcare develops and markets pharmaceutical products.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Onspira Therapeutics
Onspira Therapeutics operates as a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-11-07 | Eisai | Eisai acquired by Royalty Pharma | 330 M USD |
Investors List
General Atlantic
General Atlantic investment in Private Equity Round - Royalty Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-01 | Cytokinetics | Royalty Pharma investment in Post-IPO Debt - Cytokinetics | 450 M USD |
| 2022-05-18 | ApiJect | Royalty Pharma investment in Private Equity Round - ApiJect | 111 M USD |
| 2021-11-22 | BioCryst Pharmaceuticals | Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals | 350 M USD |
| 2020-12-07 | BioCryst Pharmaceuticals | Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals | 325 M USD |
| 2019-11-07 | Epizyme | Royalty Pharma investment in Post-IPO Equity - Epizyme | 100 M USD |
More informations about "Royalty Pharma"
Our firm | Royalty Pharma
Nov 1, 2023 Founded in 1996, Royalty Pharma has pioneered the royalty funding market and continued to innovate in life science funding. Life sciences partner of choice We are the global leader in biopharma royalty transactions, …See details»
Board of directors - Royalty Pharma
Dec 12, 2023 Prior to founding Royalty Pharma, Pablo was an investment banker at Lazard Frères in Paris and New York. Close . Bonnie Bassler, PhD. View Bio Bonnie Bassler, PhD. …See details»
Royalty Pharma - The Org
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research …See details»
Royalties in pharma: A closer look at the company which owns a …
TLDR; Royalty agreements are on the rise, and threaten to eat into big pharma’s top-line and limit their role in the biopharma ecosystem. Once little-known outside financing circles, Royalty …See details»
Royalty Pharma - Crunchbase Investor Profile
Royalty Pharma does not discover, develop, manufacture or market products. Instead, the. Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with …See details»
Royalty Pharma Highlights Accomplishments and Provides …
Jan 8, 2024 Royalty Pharma plc. 2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range. Announced transactions of $13 billion …See details»
Royalty Pharma - Investments, Portfolio & Company Exits
Royalty Pharma 's most notable exits include Teva Pharmaceuticals, Ascendis Pharma, and Cytokinetics. Which industries has this organization had the most exits in? Show . Teva …See details»
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for …
Nov 7, 2024 Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on U.S. net sales of RYTELO, ranging from 7.75% of annual net sales up to $500 …See details»
Royalty Pharma Earnings: Recent Progress With Royalty …
Nov 7, 2024 Narrow-moat Royalty Pharma’s third-quarter results came in line with our expectations. We are maintaining our $47 fair value estimate. We are encouraged by the progress with the company’s high ...See details»
Leadership team - Royalty Pharma
Since its founding in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company’s collaborations span the entire research and development ecosystem, from academic …See details»
Royalty Pharma plc (RPRX): A Strategic Investment in Life …
6 days ago Royalty Pharma plc (Nasdaq: RPRX) closed December 27 at $25.54, up 0.55% for the day, with after-hours trading slightly declining to $25.50. The stock’s range over the past …See details»
Royalty Pharma | General Atlantic
Royalty Pharma is an innovative biopharma company with a portfolio of commercial and pre-commercial drug royalties. View Site. Life Sciences. United States. 2020. Back to Investments. …See details»
Royalty Pharma - Contacts, Employees, Board Members
Royalty Pharma has 5 current employee profiles, including Senior Vice President and Chief Technology Officer Eric Schneider. Royalty Pharma has 4 board members and advisors, …See details»
Royalty Pharma - Biotech Careers
Website: Royalty Pharma. Business Area(s): Investment; Description: Transforming the Funding of Life Sciences Through Collaborative Capital. Location(s): New York NY. United States. See …See details»
Investors - Royalty Pharma
NEW YORK, NY, November 14, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or …See details»
The Royalty Pharma plc Rollercoaster: What’s Behind the Latest …
3 days ago Royalty Pharma plc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 68.14% and a profit margin of 50.52%, with a gross …See details»
Penn expecting $467M windfall from COVID-19 vaccine royalty …
1 day ago The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair settled a lawsuit out of court in late December …See details»
Royalty Pharma - Funding, Financials, Valuation & Investors
Private Equity Round - Royalty Pharma . 1: obfuscated. obfuscated — IPO & Stock Price. Edit IPO & Stock Price Section. Royalty Pharma is registered under the ticker NASDAQ:RPRX . …See details»
BioNTech settles with NIH, Penn over COVID vaccine royalties
1 day ago After the University of Pennsylvania and the U.S. | The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million through …See details»
News - Royalty Pharma
Nov 6, 2024 NEW YORK, NY, November 14, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors …See details»